4
  • Category
  • Region
U.S. (TOLL FREE)
+1 (315) 215-3225
4
U.S. (TOLL FREE)
+1 (315) 215-3225
Inhaled Antibiotics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Published Date: October 2024
|
Report Code: QYRE-Auto-30U7414
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Inhaled Antibiotics Market Insights Forecast to 2028
BUY CHAPTERS

Inhaled Antibiotics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-30U7414
Report
October 2024
Pages:142
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Inhaled Antibiotics - Market Size

The global market for Inhaled Antibiotics was estimated to be worth US$ 1677 million in 2023 and is forecast to a readjusted size of US$ 2744 million by 2030 with a CAGR of 7.3% during the forecast period 2024-2030

Inhaled Antibiotics - Market

Inhaled Antibiotics - Market

Inhaled antibiotics such as aztreonam, colistin, levofloxacin and tobramycin are the mainstay of treatment for recurrent and chronic pulmonary infections caused by P. aeruginosa or as a suppressive therapy for other infections such as Achromobacter and Stenotrophomonas.
The global inhaled antibiotics market has experienced significant growth and is expected to continue expanding in the coming years. Factors contributing to this growth include the increasing prevalence of chronic respiratory diseases, such as cystic fibrosis, non-cystic fibrosis bronchiectasis, and chronic obstructive pulmonary disease (COPD), which often require targeted antibiotic therapy delivered directly to the lungs. Additionally, the growing understanding of the importance of inhaled antibiotics in managing respiratory infections, particularly those caused by multidrug-resistant organisms, has fueled the demand for these products.
Several key players operate within the global inhaled antibiotics market, and they are continually involved in research and development efforts to introduce innovative products and formulations. Additionally, strategic collaborations, partnerships, and acquisitions have been prominent in shaping the competitive landscape of the market.
The market is also influenced by various technological advancements in drug delivery systems, including nebulizers, inhalers, and dry powder inhalers, which enhance the efficacy and convenience of administering inhaled antibiotics. Furthermore, the focus on personalized medicine and the development of customized treatment approaches for respiratory infections are driving further growth in the market.
Geographically, North America and Europe have traditionally been significant markets for inhaled antibiotics, given the high prevalence of chronic respiratory diseases in these regions and the robust healthcare infrastructure supporting their management. However, there is also a growing market in emerging economies as awareness of chronic respiratory conditions increases, and healthcare systems evolve to address these diseases.
Overall, the global inhaled antibiotics market is expected to continue to expand due to the rising prevalence of chronic respiratory diseases, advances in drug delivery technologies, and ongoing research efforts aimed at developing effective treatments for respiratory infections.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Inhaled Antibiotics, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Inhaled Antibiotics by region & country, by Type, and by Application.
The Inhaled Antibiotics market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Inhaled Antibiotics.
Market Segmentation

Scope of Inhaled Antibiotics - Market Report

Report Metric Details
Report Name Inhaled Antibiotics - Market
Forecasted market size in 2030 US$ 2744 million
CAGR 7.3%
Forecasted years 2024 - 2030
Segment by Type:
  • Nebulized
  • Dry Powder
Segment by Application
  • Ventilator-associated Pneumonia
  • Ventilator-associated Bronchitis
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Aradigm, Gilead Sciences, Lupin, Polyphor, Insmed Incorporated, Pharmaero, Savara Pharmaceuticals, Joincare Pharmaceutical Group, Pharmaxis Ltd, Aridis Pharmaceuticals, Novartis Pharmaceuticals, PARI Pharma, Vertex Pharmaceuticals, Bayer AG, Grifols, Chiesi Farmaceutici
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 2: Detailed analysis of Inhaled Antibiotics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 5: Sales, revenue of Inhaled Antibiotics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 6: Sales, revenue of Inhaled Antibiotics in country level. It provides sigmate data by Type, and by Application for each country/region.
  • Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 9: Conclusion.

FAQ for this report

What is the Inhaled Antibiotics - Market size in 2030?

Ans: The Inhaled Antibiotics - Market size in 2030 will be US$ 2744 million.

Who are the main players in the Inhaled Antibiotics - Market report?

Ans: The main players in the Inhaled Antibiotics - Market are Aradigm, Gilead Sciences, Lupin, Polyphor, Insmed Incorporated, Pharmaero, Savara Pharmaceuticals, Joincare Pharmaceutical Group, Pharmaxis Ltd, Aridis Pharmaceuticals, Novartis Pharmaceuticals, PARI Pharma, Vertex Pharmaceuticals, Bayer AG, Grifols, Chiesi Farmaceutici

What are the Application segmentation covered in the Inhaled Antibiotics - Market report?

Ans: The Applications covered in the Inhaled Antibiotics - Market report are Ventilator-associated Pneumonia, Ventilator-associated Bronchitis, Others

What are the Type segmentation covered in the Inhaled Antibiotics - Market report?

Ans: The Types covered in the Inhaled Antibiotics - Market report are Nebulized, Dry Powder

1 Market Overview
1.1 Inhaled Antibiotics Product Introduction
1.2 Global Inhaled Antibiotics Market Size Forecast
1.2.1 Global Inhaled Antibiotics Sales Value (2019-2030)
1.2.2 Global Inhaled Antibiotics Sales Volume (2019-2030)
1.2.3 Global Inhaled Antibiotics Sales Price (2019-2030)
1.3 Inhaled Antibiotics Market Trends & Drivers
1.3.1 Inhaled Antibiotics Industry Trends
1.3.2 Inhaled Antibiotics Market Drivers & Opportunity
1.3.3 Inhaled Antibiotics Market Challenges
1.3.4 Inhaled Antibiotics Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Inhaled Antibiotics Players Revenue Ranking (2023)
2.2 Global Inhaled Antibiotics Revenue by Company (2019-2024)
2.3 Global Inhaled Antibiotics Players Sales Volume Ranking (2023)
2.4 Global Inhaled Antibiotics Sales Volume by Company Players (2019-2024)
2.5 Global Inhaled Antibiotics Average Price by Company (2019-2024)
2.6 Key Manufacturers Inhaled Antibiotics Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Inhaled Antibiotics Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Inhaled Antibiotics
2.9 Inhaled Antibiotics Market Competitive Analysis
2.9.1 Inhaled Antibiotics Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Inhaled Antibiotics Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inhaled Antibiotics as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Nebulized
3.1.2 Dry Powder
3.2 Global Inhaled Antibiotics Sales Value by Type
3.2.1 Global Inhaled Antibiotics Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Inhaled Antibiotics Sales Value, by Type (2019-2030)
3.2.3 Global Inhaled Antibiotics Sales Value, by Type (%) (2019-2030)
3.3 Global Inhaled Antibiotics Sales Volume by Type
3.3.1 Global Inhaled Antibiotics Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Inhaled Antibiotics Sales Volume, by Type (2019-2030)
3.3.3 Global Inhaled Antibiotics Sales Volume, by Type (%) (2019-2030)
3.4 Global Inhaled Antibiotics Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Ventilator-associated Pneumonia
4.1.2 Ventilator-associated Bronchitis
4.1.3 Others
4.2 Global Inhaled Antibiotics Sales Value by Application
4.2.1 Global Inhaled Antibiotics Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Inhaled Antibiotics Sales Value, by Application (2019-2030)
4.2.3 Global Inhaled Antibiotics Sales Value, by Application (%) (2019-2030)
4.3 Global Inhaled Antibiotics Sales Volume by Application
4.3.1 Global Inhaled Antibiotics Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Inhaled Antibiotics Sales Volume, by Application (2019-2030)
4.3.3 Global Inhaled Antibiotics Sales Volume, by Application (%) (2019-2030)
4.4 Global Inhaled Antibiotics Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Inhaled Antibiotics Sales Value by Region
5.1.1 Global Inhaled Antibiotics Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Inhaled Antibiotics Sales Value by Region (2019-2024)
5.1.3 Global Inhaled Antibiotics Sales Value by Region (2025-2030)
5.1.4 Global Inhaled Antibiotics Sales Value by Region (%), (2019-2030)
5.2 Global Inhaled Antibiotics Sales Volume by Region
5.2.1 Global Inhaled Antibiotics Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Inhaled Antibiotics Sales Volume by Region (2019-2024)
5.2.3 Global Inhaled Antibiotics Sales Volume by Region (2025-2030)
5.2.4 Global Inhaled Antibiotics Sales Volume by Region (%), (2019-2030)
5.3 Global Inhaled Antibiotics Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Inhaled Antibiotics Sales Value, 2019-2030
5.4.2 North America Inhaled Antibiotics Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Inhaled Antibiotics Sales Value, 2019-2030
5.5.2 Europe Inhaled Antibiotics Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Inhaled Antibiotics Sales Value, 2019-2030
5.6.2 Asia Pacific Inhaled Antibiotics Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Inhaled Antibiotics Sales Value, 2019-2030
5.7.2 South America Inhaled Antibiotics Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Inhaled Antibiotics Sales Value, 2019-2030
5.8.2 Middle East & Africa Inhaled Antibiotics Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Inhaled Antibiotics Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Inhaled Antibiotics Sales Value
6.2.1 Key Countries/Regions Inhaled Antibiotics Sales Value, 2019-2030
6.2.2 Key Countries/Regions Inhaled Antibiotics Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Inhaled Antibiotics Sales Value, 2019-2030
6.3.2 United States Inhaled Antibiotics Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Inhaled Antibiotics Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Inhaled Antibiotics Sales Value, 2019-2030
6.4.2 Europe Inhaled Antibiotics Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Inhaled Antibiotics Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Inhaled Antibiotics Sales Value, 2019-2030
6.5.2 China Inhaled Antibiotics Sales Value by Type (%), 2023 VS 2030
6.5.3 China Inhaled Antibiotics Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Inhaled Antibiotics Sales Value, 2019-2030
6.6.2 Japan Inhaled Antibiotics Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Inhaled Antibiotics Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Inhaled Antibiotics Sales Value, 2019-2030
6.7.2 South Korea Inhaled Antibiotics Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Inhaled Antibiotics Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Inhaled Antibiotics Sales Value, 2019-2030
6.8.2 Southeast Asia Inhaled Antibiotics Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Inhaled Antibiotics Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Inhaled Antibiotics Sales Value, 2019-2030
6.9.2 India Inhaled Antibiotics Sales Value by Type (%), 2023 VS 2030
6.9.3 India Inhaled Antibiotics Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Aradigm
7.1.1 Aradigm Company Information
7.1.2 Aradigm Introduction and Business Overview
7.1.3 Aradigm Inhaled Antibiotics Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Aradigm Inhaled Antibiotics Product Offerings
7.1.5 Aradigm Recent Development
7.2 Gilead Sciences
7.2.1 Gilead Sciences Company Information
7.2.2 Gilead Sciences Introduction and Business Overview
7.2.3 Gilead Sciences Inhaled Antibiotics Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Gilead Sciences Inhaled Antibiotics Product Offerings
7.2.5 Gilead Sciences Recent Development
7.3 Lupin
7.3.1 Lupin Company Information
7.3.2 Lupin Introduction and Business Overview
7.3.3 Lupin Inhaled Antibiotics Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Lupin Inhaled Antibiotics Product Offerings
7.3.5 Lupin Recent Development
7.4 Polyphor
7.4.1 Polyphor Company Information
7.4.2 Polyphor Introduction and Business Overview
7.4.3 Polyphor Inhaled Antibiotics Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Polyphor Inhaled Antibiotics Product Offerings
7.4.5 Polyphor Recent Development
7.5 Insmed Incorporated
7.5.1 Insmed Incorporated Company Information
7.5.2 Insmed Incorporated Introduction and Business Overview
7.5.3 Insmed Incorporated Inhaled Antibiotics Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Insmed Incorporated Inhaled Antibiotics Product Offerings
7.5.5 Insmed Incorporated Recent Development
7.6 Pharmaero
7.6.1 Pharmaero Company Information
7.6.2 Pharmaero Introduction and Business Overview
7.6.3 Pharmaero Inhaled Antibiotics Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Pharmaero Inhaled Antibiotics Product Offerings
7.6.5 Pharmaero Recent Development
7.7 Savara Pharmaceuticals
7.7.1 Savara Pharmaceuticals Company Information
7.7.2 Savara Pharmaceuticals Introduction and Business Overview
7.7.3 Savara Pharmaceuticals Inhaled Antibiotics Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Savara Pharmaceuticals Inhaled Antibiotics Product Offerings
7.7.5 Savara Pharmaceuticals Recent Development
7.8 Joincare Pharmaceutical Group
7.8.1 Joincare Pharmaceutical Group Company Information
7.8.2 Joincare Pharmaceutical Group Introduction and Business Overview
7.8.3 Joincare Pharmaceutical Group Inhaled Antibiotics Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Joincare Pharmaceutical Group Inhaled Antibiotics Product Offerings
7.8.5 Joincare Pharmaceutical Group Recent Development
7.9 Pharmaxis Ltd
7.9.1 Pharmaxis Ltd Company Information
7.9.2 Pharmaxis Ltd Introduction and Business Overview
7.9.3 Pharmaxis Ltd Inhaled Antibiotics Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Pharmaxis Ltd Inhaled Antibiotics Product Offerings
7.9.5 Pharmaxis Ltd Recent Development
7.10 Aridis Pharmaceuticals
7.10.1 Aridis Pharmaceuticals Company Information
7.10.2 Aridis Pharmaceuticals Introduction and Business Overview
7.10.3 Aridis Pharmaceuticals Inhaled Antibiotics Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Aridis Pharmaceuticals Inhaled Antibiotics Product Offerings
7.10.5 Aridis Pharmaceuticals Recent Development
7.11 Novartis Pharmaceuticals
7.11.1 Novartis Pharmaceuticals Company Information
7.11.2 Novartis Pharmaceuticals Introduction and Business Overview
7.11.3 Novartis Pharmaceuticals Inhaled Antibiotics Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Novartis Pharmaceuticals Inhaled Antibiotics Product Offerings
7.11.5 Novartis Pharmaceuticals Recent Development
7.12 PARI Pharma
7.12.1 PARI Pharma Company Information
7.12.2 PARI Pharma Introduction and Business Overview
7.12.3 PARI Pharma Inhaled Antibiotics Sales, Revenue and Gross Margin (2019-2024)
7.12.4 PARI Pharma Inhaled Antibiotics Product Offerings
7.12.5 PARI Pharma Recent Development
7.13 Vertex Pharmaceuticals
7.13.1 Vertex Pharmaceuticals Company Information
7.13.2 Vertex Pharmaceuticals Introduction and Business Overview
7.13.3 Vertex Pharmaceuticals Inhaled Antibiotics Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Vertex Pharmaceuticals Inhaled Antibiotics Product Offerings
7.13.5 Vertex Pharmaceuticals Recent Development
7.14 Bayer AG
7.14.1 Bayer AG Company Information
7.14.2 Bayer AG Introduction and Business Overview
7.14.3 Bayer AG Inhaled Antibiotics Sales, Revenue and Gross Margin (2019-2024)
7.14.4 Bayer AG Inhaled Antibiotics Product Offerings
7.14.5 Bayer AG Recent Development
7.15 Grifols
7.15.1 Grifols Company Information
7.15.2 Grifols Introduction and Business Overview
7.15.3 Grifols Inhaled Antibiotics Sales, Revenue and Gross Margin (2019-2024)
7.15.4 Grifols Inhaled Antibiotics Product Offerings
7.15.5 Grifols Recent Development
7.16 Chiesi Farmaceutici
7.16.1 Chiesi Farmaceutici Company Information
7.16.2 Chiesi Farmaceutici Introduction and Business Overview
7.16.3 Chiesi Farmaceutici Inhaled Antibiotics Sales, Revenue and Gross Margin (2019-2024)
7.16.4 Chiesi Farmaceutici Inhaled Antibiotics Product Offerings
7.16.5 Chiesi Farmaceutici Recent Development
8 Industry Chain Analysis
8.1 Inhaled Antibiotics Industrial Chain
8.2 Inhaled Antibiotics Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Inhaled Antibiotics Sales Model
8.5.2 Sales Channel
8.5.3 Inhaled Antibiotics Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
    Table 1. Inhaled Antibiotics Market Trends
    Table 2. Inhaled Antibiotics Market Drivers & Opportunity
    Table 3. Inhaled Antibiotics Market Challenges
    Table 4. Inhaled Antibiotics Market Restraints
    Table 5. Global Inhaled Antibiotics Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Inhaled Antibiotics Revenue Market Share by Company (2019-2024)
    Table 7. Global Inhaled Antibiotics Sales Volume by Company (2019-2024) & (K Units)
    Table 8. Global Inhaled Antibiotics Sales Volume Market Share by Company (2019-2024)
    Table 9. Global Market Inhaled Antibiotics Price by Company (2019-2024) & (US$/Unit)
    Table 10. Key Manufacturers Inhaled Antibiotics Manufacturing Base Distribution and Headquarters
    Table 11. Key Manufacturers Inhaled Antibiotics Product Type
    Table 12. Key Manufacturers Time to Begin Mass Production of Inhaled Antibiotics
    Table 13. Global Inhaled Antibiotics Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inhaled Antibiotics as of 2023)
    Table 15. Mergers & Acquisitions, Expansion Plans
    Table 16. Global Inhaled Antibiotics Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 17. Global Inhaled Antibiotics Sales Value by Type (2019-2024) & (US$ Million)
    Table 18. Global Inhaled Antibiotics Sales Value by Type (2025-2030) & (US$ Million)
    Table 19. Global Inhaled Antibiotics Sales Market Share in Value by Type (2019-2024) & (%)
    Table 20. Global Inhaled Antibiotics Sales Market Share in Value by Type (2025-2030) & (%)
    Table 21. Global Inhaled Antibiotics Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
    Table 22. Global Inhaled Antibiotics Sales Volume by Type (2019-2024) & (K Units)
    Table 23. Global Inhaled Antibiotics Sales Volume by Type (2025-2030) & (K Units)
    Table 24. Global Inhaled Antibiotics Sales Market Share in Volume by Type (2019-2024) & (%)
    Table 25. Global Inhaled Antibiotics Sales Market Share in Volume by Type (2025-2030) & (%)
    Table 26. Global Inhaled Antibiotics Price by Type (2019-2024) & (US$/Unit)
    Table 27. Global Inhaled Antibiotics Price by Type (2025-2030) & (US$/Unit)
    Table 28. Global Inhaled Antibiotics Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 29. Global Inhaled Antibiotics Sales Value by Application (2019-2024) & (US$ Million)
    Table 30. Global Inhaled Antibiotics Sales Value by Application (2025-2030) & (US$ Million)
    Table 31. Global Inhaled Antibiotics Sales Market Share in Value by Application (2019-2024) & (%)
    Table 32. Global Inhaled Antibiotics Sales Market Share in Value by Application (2025-2030) & (%)
    Table 33. Global Inhaled Antibiotics Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
    Table 34. Global Inhaled Antibiotics Sales Volume by Application (2019-2024) & (K Units)
    Table 35. Global Inhaled Antibiotics Sales Volume by Application (2025-2030) & (K Units)
    Table 36. Global Inhaled Antibiotics Sales Market Share in Volume by Application (2019-2024) & (%)
    Table 37. Global Inhaled Antibiotics Sales Market Share in Volume by Application (2025-2030) & (%)
    Table 38. Global Inhaled Antibiotics Price by Application (2019-2024) & (US$/Unit)
    Table 39. Global Inhaled Antibiotics Price by Application (2025-2030) & (US$/Unit)
    Table 40. Global Inhaled Antibiotics Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Global Inhaled Antibiotics Sales Value by Region (2019-2024) & (US$ Million)
    Table 42. Global Inhaled Antibiotics Sales Value by Region (2025-2030) & (US$ Million)
    Table 43. Global Inhaled Antibiotics Sales Value by Region (2019-2024) & (%)
    Table 44. Global Inhaled Antibiotics Sales Value by Region (2025-2030) & (%)
    Table 45. Global Inhaled Antibiotics Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
    Table 46. Global Inhaled Antibiotics Sales Volume by Region (2019-2024) & (K Units)
    Table 47. Global Inhaled Antibiotics Sales Volume by Region (2025-2030) & (K Units)
    Table 48. Global Inhaled Antibiotics Sales Volume by Region (2019-2024) & (%)
    Table 49. Global Inhaled Antibiotics Sales Volume by Region (2025-2030) & (%)
    Table 50. Global Inhaled Antibiotics Average Price by Region (2019-2024) & (US$/Unit)
    Table 51. Global Inhaled Antibiotics Average Price by Region (2025-2030) & (US$/Unit)
    Table 52. Key Countries/Regions Inhaled Antibiotics Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 53. Key Countries/Regions Inhaled Antibiotics Sales Value, (2019-2024) & (US$ Million)
    Table 54. Key Countries/Regions Inhaled Antibiotics Sales Value, (2025-2030) & (US$ Million)
    Table 55. Key Countries/Regions Inhaled Antibiotics Sales Volume, (2019-2024) & (K Units)
    Table 56. Key Countries/Regions Inhaled Antibiotics Sales Volume, (2025-2030) & (K Units)
    Table 57. Aradigm Company Information
    Table 58. Aradigm Introduction and Business Overview
    Table 59. Aradigm Inhaled Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 60. Aradigm Inhaled Antibiotics Product Offerings
    Table 61. Aradigm Recent Development
    Table 62. Gilead Sciences Company Information
    Table 63. Gilead Sciences Introduction and Business Overview
    Table 64. Gilead Sciences Inhaled Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 65. Gilead Sciences Inhaled Antibiotics Product Offerings
    Table 66. Gilead Sciences Recent Development
    Table 67. Lupin Company Information
    Table 68. Lupin Introduction and Business Overview
    Table 69. Lupin Inhaled Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 70. Lupin Inhaled Antibiotics Product Offerings
    Table 71. Lupin Recent Development
    Table 72. Polyphor Company Information
    Table 73. Polyphor Introduction and Business Overview
    Table 74. Polyphor Inhaled Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 75. Polyphor Inhaled Antibiotics Product Offerings
    Table 76. Polyphor Recent Development
    Table 77. Insmed Incorporated Company Information
    Table 78. Insmed Incorporated Introduction and Business Overview
    Table 79. Insmed Incorporated Inhaled Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 80. Insmed Incorporated Inhaled Antibiotics Product Offerings
    Table 81. Insmed Incorporated Recent Development
    Table 82. Pharmaero Company Information
    Table 83. Pharmaero Introduction and Business Overview
    Table 84. Pharmaero Inhaled Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 85. Pharmaero Inhaled Antibiotics Product Offerings
    Table 86. Pharmaero Recent Development
    Table 87. Savara Pharmaceuticals Company Information
    Table 88. Savara Pharmaceuticals Introduction and Business Overview
    Table 89. Savara Pharmaceuticals Inhaled Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 90. Savara Pharmaceuticals Inhaled Antibiotics Product Offerings
    Table 91. Savara Pharmaceuticals Recent Development
    Table 92. Joincare Pharmaceutical Group Company Information
    Table 93. Joincare Pharmaceutical Group Introduction and Business Overview
    Table 94. Joincare Pharmaceutical Group Inhaled Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 95. Joincare Pharmaceutical Group Inhaled Antibiotics Product Offerings
    Table 96. Joincare Pharmaceutical Group Recent Development
    Table 97. Pharmaxis Ltd Company Information
    Table 98. Pharmaxis Ltd Introduction and Business Overview
    Table 99. Pharmaxis Ltd Inhaled Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 100. Pharmaxis Ltd Inhaled Antibiotics Product Offerings
    Table 101. Pharmaxis Ltd Recent Development
    Table 102. Aridis Pharmaceuticals Company Information
    Table 103. Aridis Pharmaceuticals Introduction and Business Overview
    Table 104. Aridis Pharmaceuticals Inhaled Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 105. Aridis Pharmaceuticals Inhaled Antibiotics Product Offerings
    Table 106. Aridis Pharmaceuticals Recent Development
    Table 107. Novartis Pharmaceuticals Company Information
    Table 108. Novartis Pharmaceuticals Introduction and Business Overview
    Table 109. Novartis Pharmaceuticals Inhaled Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 110. Novartis Pharmaceuticals Inhaled Antibiotics Product Offerings
    Table 111. Novartis Pharmaceuticals Recent Development
    Table 112. PARI Pharma Company Information
    Table 113. PARI Pharma Introduction and Business Overview
    Table 114. PARI Pharma Inhaled Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 115. PARI Pharma Inhaled Antibiotics Product Offerings
    Table 116. PARI Pharma Recent Development
    Table 117. Vertex Pharmaceuticals Company Information
    Table 118. Vertex Pharmaceuticals Introduction and Business Overview
    Table 119. Vertex Pharmaceuticals Inhaled Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 120. Vertex Pharmaceuticals Inhaled Antibiotics Product Offerings
    Table 121. Vertex Pharmaceuticals Recent Development
    Table 122. Bayer AG Company Information
    Table 123. Bayer AG Introduction and Business Overview
    Table 124. Bayer AG Inhaled Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 125. Bayer AG Inhaled Antibiotics Product Offerings
    Table 126. Bayer AG Recent Development
    Table 127. Grifols Company Information
    Table 128. Grifols Introduction and Business Overview
    Table 129. Grifols Inhaled Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 130. Grifols Inhaled Antibiotics Product Offerings
    Table 131. Grifols Recent Development
    Table 132. Chiesi Farmaceutici Company Information
    Table 133. Chiesi Farmaceutici Introduction and Business Overview
    Table 134. Chiesi Farmaceutici Inhaled Antibiotics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 135. Chiesi Farmaceutici Inhaled Antibiotics Product Offerings
    Table 136. Chiesi Farmaceutici Recent Development
    Table 137. Key Raw Materials Lists
    Table 138. Raw Materials Key Suppliers Lists
    Table 139. Inhaled Antibiotics Downstream Customers
    Table 140. Inhaled Antibiotics Distributors List
    Table 141. Research Programs/Design for This Report
    Table 142. Key Data Information from Secondary Sources
    Table 143. Key Data Information from Primary Sources
List of Figures
    Figure 1. Inhaled Antibiotics Product Picture
    Figure 2. Global Inhaled Antibiotics Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Inhaled Antibiotics Sales Value (2019-2030) & (US$ Million)
    Figure 4. Global Inhaled Antibiotics Sales Volume (2019-2030) & (K Units)
    Figure 5. Global Inhaled Antibiotics Sales Price (2019-2030) & (US$/Unit)
    Figure 6. Inhaled Antibiotics Report Years Considered
    Figure 7. Global Inhaled Antibiotics Players Revenue Ranking (2023) & (US$ Million)
    Figure 8. Global Inhaled Antibiotics Players Sales Volume Ranking (2023) & (K Units)
    Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Inhaled Antibiotics Revenue in 2023
    Figure 10. Inhaled Antibiotics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 11. Nebulized Picture
    Figure 12. Dry Powder Picture
    Figure 13. Global Inhaled Antibiotics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 14. Global Inhaled Antibiotics Sales Value Market Share by Type, 2023 & 2030
    Figure 15. Global Inhaled Antibiotics Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
    Figure 16. Global Inhaled Antibiotics Sales Volume Market Share by Type, 2023 & 2030
    Figure 17. Global Inhaled Antibiotics Price by Type (2019-2030) & (US$/Unit)
    Figure 18. Product Picture of Ventilator-associated Pneumonia
    Figure 19. Product Picture of Ventilator-associated Bronchitis
    Figure 20. Product Picture of Others
    Figure 21. Global Inhaled Antibiotics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 22. Global Inhaled Antibiotics Sales Value Market Share by Application, 2023 & 2030
    Figure 23. Global Inhaled Antibiotics Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
    Figure 24. Global Inhaled Antibiotics Sales Volume Market Share by Application, 2023 & 2030
    Figure 25. Global Inhaled Antibiotics Price by Application (2019-2030) & (US$/Unit)
    Figure 26. North America Inhaled Antibiotics Sales Value (2019-2030) & (US$ Million)
    Figure 27. North America Inhaled Antibiotics Sales Value by Country (%), 2023 VS 2030
    Figure 28. Europe Inhaled Antibiotics Sales Value (2019-2030) & (US$ Million)
    Figure 29. Europe Inhaled Antibiotics Sales Value by Country (%), 2023 VS 2030
    Figure 30. Asia Pacific Inhaled Antibiotics Sales Value (2019-2030) & (US$ Million)
    Figure 31. Asia Pacific Inhaled Antibiotics Sales Value by Country (%), 2023 VS 2030
    Figure 32. South America Inhaled Antibiotics Sales Value (2019-2030) & (US$ Million)
    Figure 33. South America Inhaled Antibiotics Sales Value by Country (%), 2023 VS 2030
    Figure 34. Middle East & Africa Inhaled Antibiotics Sales Value (2019-2030) & (US$ Million)
    Figure 35. Middle East & Africa Inhaled Antibiotics Sales Value by Country (%), 2023 VS 2030
    Figure 36. Key Countries/Regions Inhaled Antibiotics Sales Value (%), (2019-2030)
    Figure 37. Key Countries/Regions Inhaled Antibiotics Sales Volume (%), (2019-2030)
    Figure 38. United States Inhaled Antibiotics Sales Value, (2019-2030) & (US$ Million)
    Figure 39. United States Inhaled Antibiotics Sales Value by Type (%), 2023 VS 2030
    Figure 40. United States Inhaled Antibiotics Sales Value by Application (%), 2023 VS 2030
    Figure 41. Europe Inhaled Antibiotics Sales Value, (2019-2030) & (US$ Million)
    Figure 42. Europe Inhaled Antibiotics Sales Value by Type (%), 2023 VS 2030
    Figure 43. Europe Inhaled Antibiotics Sales Value by Application (%), 2023 VS 2030
    Figure 44. China Inhaled Antibiotics Sales Value, (2019-2030) & (US$ Million)
    Figure 45. China Inhaled Antibiotics Sales Value by Type (%), 2023 VS 2030
    Figure 46. China Inhaled Antibiotics Sales Value by Application (%), 2023 VS 2030
    Figure 47. Japan Inhaled Antibiotics Sales Value, (2019-2030) & (US$ Million)
    Figure 48. Japan Inhaled Antibiotics Sales Value by Type (%), 2023 VS 2030
    Figure 49. Japan Inhaled Antibiotics Sales Value by Application (%), 2023 VS 2030
    Figure 50. South Korea Inhaled Antibiotics Sales Value, (2019-2030) & (US$ Million)
    Figure 51. South Korea Inhaled Antibiotics Sales Value by Type (%), 2023 VS 2030
    Figure 52. South Korea Inhaled Antibiotics Sales Value by Application (%), 2023 VS 2030
    Figure 53. Southeast Asia Inhaled Antibiotics Sales Value, (2019-2030) & (US$ Million)
    Figure 54. Southeast Asia Inhaled Antibiotics Sales Value by Type (%), 2023 VS 2030
    Figure 55. Southeast Asia Inhaled Antibiotics Sales Value by Application (%), 2023 VS 2030
    Figure 56. India Inhaled Antibiotics Sales Value, (2019-2030) & (US$ Million)
    Figure 57. India Inhaled Antibiotics Sales Value by Type (%), 2023 VS 2030
    Figure 58. India Inhaled Antibiotics Sales Value by Application (%), 2023 VS 2030
    Figure 59. Inhaled Antibiotics Industrial Chain
    Figure 60. Inhaled Antibiotics Manufacturing Cost Structure
    Figure 61. Channels of Distribution (Direct Sales, and Distribution)
    Figure 62. Bottom-up and Top-down Approaches for This Report
    Figure 63. Data Triangulation
    Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$3950

This license allows only one user to access the PDF.
Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

SecuX Technology Inc

SIMILAR REPORTS